NCT06678555View on ClinicalTrials.gov

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.

RecruitingOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

July 4, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Lorlatinib

Lorlatinib is an ALK/ROS1 tyrosin kinase inhibitor.

Trial Locations (1)

Unknown

RECRUITING

Pfizer Inc, Taipei

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06678555 - A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out. | Biotech Hunter | Biotech Hunter